Purinogenic immunodeficiency diseases: selective toxicity of deoxyribonucleosides for T cells.
about
Cloning and expression of human deoxycytidine kinase cDNAElevated adenosine deaminase activity and hereditary hemolytic anemia. Evidence for abnormal translational control of protein synthesisImmucillin H, a powerful transition-state analog inhibitor of purine nucleoside phosphorylase, selectively inhibits human T lymphocytesMolecular analysis of mutations in a patient with purine nucleoside phosphorylase deficiencyDistribution of 5'-nucleotidase in human lymphoid tissuesDeoxyadenosine triphosphate as a mediator of deoxyguanosine toxicity in cultured T lymphoblastsDeoxycytidine kinase-mediated toxicity of deoxyadenosine analogs toward malignant human lymphoblasts in vitro and toward murine L1210 leukemia in vivoThe metabolism of deoxyguanosine and guanosine in human B and T lymphoblasts. A role for deoxyguanosine kinase activity in the selective T-cell defect associated with purine nucleoside phosphorylase deficiencyDecreased methionine synthesis in purine nucleoside-treated T and B lymphoblasts and reversal by homocysteine2'-deoxyguanosine toxicity for B and mature T lymphoid cell lines is mediated by guanine ribonucleotide accumulationAdenosine kinase inhibition promotes survival of fetal adenosine deaminase-deficient thymocytes by blocking dATP accumulationNelarabine in the treatment of pediatric and adult patients with T-cell acute lymphoblastic leukemia and lymphoma.Loop-tryptophan human purine nucleoside phosphorylase reveals submillisecond protein dynamics.Adenosine deaminase polymorphism. Associations at clinical level suggest a role in cell functions and immune reactions.Conformational states of human purine nucleoside phosphorylase at rest, at work, and with transition state analoguesAdenosine deaminase deficiency with normal immune function. An acidic enzyme mutation.Enzyme and membrane markers in leukaemia: recent developmentsInfluence of bone marrow stromal microenvironment on forodesine-induced responses in CLL primary cells.Characterization of the deoxycytidine kinase promoter in human lymphoblast cell linesMechanism of deoxyadenosine and 2-chlorodeoxyadenosine toxicity to nondividing human lymphocytesRole of nelarabine in the treatment of T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma.Specific cytotoxicity of arabinosylguanine toward cultured T lymphoblastsThe pentostatin plus cyclophosphamide nonmyeloablative regimen induces durable host T cell functional deficits and prevents murine marrow allograft rejection.Pentostatin plus cyclophosphamide safely and effectively prevents immunotoxin immunogenicity in murine hosts.Ecto-5'-nucleotidase activity in human T cell subsets. Decreased numbers of ecto-5'-nucleotidase positive cells from both OKT4+ and OKT8+ cells in patients with hypogammaglobulinemia.Nucleoside kinases in T and B lymphoblasts distinguished by autoradiography.A proof-of-principle pharmacokinetic, pharmacodynamic, and clinical study with purine nucleoside phosphorylase inhibitor immucillin-H (BCX-1777, forodesine)Nelarabine: a nucleoside analog with efficacy in T-cell and other leukemias.Conversion of a stem cell leukemia from a T-lymphoid to a myeloid phenotype induced by the adenosine deaminase inhibitor 2'-deoxycoformycin.Antileukemic and immunosuppressive activity of 2-chloro-2'-deoxyadenosine.Mechanism of deoxyadenosine-induced catabolism of adenine ribonucleotides in adenosine deaminase-inhibited human T lymphoblastoid cellsPossible metabolic basis for the different immunodeficient states associated with genetic deficiencies of adenosine deaminase and purine nucleoside phosphorylaseATP depletion as a consequence of adenosine deaminase inhibition in man.Nelarabine: efficacy in the treatment of clinical malignancies.Remote mutations and active site dynamics correlate with catalytic properties of purine nucleoside phosphorylase.Novel purine nucleoside analogues for T-cell-lineage acute lymphoblastic leukaemia and lymphoma.Purinogenic immunodeficiency diseases. Differential effects of deoxyadenosine and deoxyguanosine on DNA synthesis in human T lymphoblasts.Biochemical basis for the enhanced toxicity of deoxyribonucleosides toward malignant human T cell linesBiochemical basis for differential deoxyadenosine toxicity to T and B lymphoblasts: role for 5'-nucleotidase.Insights into thymic purine metabolism and adenosine deaminase deficiency revealed by transgenic mice overexpressing ecto-5'-nucleotidase (CD73).
P2860
Q24336076-0FE4338C-03DB-4F59-9F11-0FC41DE553D3Q24563746-61050F51-0108-4CE9-9753-D709E63CF9A0Q24635226-00FBC906-63B2-43D0-AE9C-5D65F44B225AQ24669781-B941DB81-27CB-49AB-B2BF-64A7833E984FQ28291580-91743280-98B6-4A8F-956F-0AA6B6361C7CQ28361665-CA40D481-5683-4857-9650-E65985224603Q28366064-00D6A6DA-C7C4-4DB2-9005-051A9C35A972Q28366279-94F1E846-E8F1-4036-8B59-B652CCE9765BQ28366359-6AA1103C-87EA-4453-BA06-E49D6A740C0BQ28366368-E591CB4E-21B3-4C6A-B725-B8F03F2D4773Q28504862-8D0F6638-00FE-49F5-AB56-5A761563B5B2Q30240892-9855CA4D-5E3A-46B0-BDC1-DE68D7924286Q33405379-3B1787E2-A871-4BC4-BF2F-0BD3A3AA450FQ33668928-0967CBD4-1F27-4EC9-9C91-42C378B27A95Q33706528-6BACFEE4-3CB7-46B6-A9F0-FC98059300E1Q33822019-74EB471F-2397-4135-AD52-8D0265FB33D8Q33848719-5B1107A4-3FC3-40EE-88BC-A8C07C982A92Q34122323-A4B0FB4D-405B-420D-9683-728192969C06Q34208439-3A328AF9-3F57-445A-BCEF-C347FCC3CDF3Q34529077-2DB87AEB-B192-4EF5-BE3B-1297E0268E75Q34592646-A6159496-943A-49F3-B7C2-BB2D4B9D51CAQ34614378-79D0AA98-3CDA-4028-8108-187270B62CABQ34700443-82FD191C-C52F-474E-AE60-FC499F052A09Q35023967-A49382B7-B105-44EE-8CBC-C84C864F853DQ35205555-0B4A7AA3-A09B-471B-A31D-C6929AB27D14Q35609503-AC4CF79C-599F-4C17-ACED-A152DB4B5056Q35848202-4766316C-DC58-4DB6-960F-7429F47EB382Q36115780-543F49D5-1D62-485E-8222-818B7A7CDC36Q36246013-CB665D7F-6917-4248-9513-17A93949B24FQ36267473-431D3436-2A58-4E74-81DA-F20591C12AEFQ36292682-48E52CFE-1589-442D-AE36-8411F1D47FBDQ36300440-ABA1183B-2F85-4196-8BD3-2B7B2AAE5F10Q36412113-AE2F5843-B4BB-42AE-9859-23135B084DB9Q36572507-75DA6D78-D2E2-4194-8CA9-2326EAB4AEB0Q36632125-5926AEBE-026E-4C72-8251-73632A434A4FQ36654341-7923EC88-2378-4D64-8936-E67FECB2F57DQ37017801-AF29536C-51BD-46AB-9426-1C1D64160732Q37331315-F432EEE5-C996-4000-ADB3-A7A3E0601B18Q37331357-5C579D1F-F24E-4C8A-9D00-2CF97317328DQ37363358-CAE2D5F9-6393-4859-9838-C31295D09BD0
P2860
Purinogenic immunodeficiency diseases: selective toxicity of deoxyribonucleosides for T cells.
description
1978 nî lūn-bûn
@nan
1978年の論文
@ja
1978年論文
@yue
1978年論文
@zh-hant
1978年論文
@zh-hk
1978年論文
@zh-mo
1978年論文
@zh-tw
1978年论文
@wuu
1978年论文
@zh
1978年论文
@zh-cn
name
Purinogenic immunodeficiency d ...... xyribonucleosides for T cells.
@ast
Purinogenic immunodeficiency d ...... xyribonucleosides for T cells.
@en
type
label
Purinogenic immunodeficiency d ...... xyribonucleosides for T cells.
@ast
Purinogenic immunodeficiency d ...... xyribonucleosides for T cells.
@en
prefLabel
Purinogenic immunodeficiency d ...... xyribonucleosides for T cells.
@ast
Purinogenic immunodeficiency d ...... xyribonucleosides for T cells.
@en
P2093
P2860
P356
P1476
Purinogenic immunodeficiency d ...... xyribonucleosides for T cells.
@en
P2093
P2860
P304
P356
10.1073/PNAS.75.10.5011
P407
P577
1978-10-01T00:00:00Z